Advertisement
Home »

Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis.

Jan 16, 2023

ABOUT THE CONTRIBUTORS

  • Catherine Leroy

    Univ. Lille, CNRS, Inserm, UMR9020-U1277 – CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; Unité tumorigenèse et résistance aux traitements, Institut Pasteur de Lille, F-59000 Lille, France.

    Sacha Spelier

    Pediatric Respiratory Medicine, Wilhelmina Children’s Hospital, University Medical Center, Utrecht University, 3584 EA Utrecht, The Netherlands; Regenerative Medicine Utrecht, University Medical Center, Utrecht University, 3584 CT Utrecht, The Netherlands; Centre for Living Technologies, University Medical Center, Utrecht University, 3584 CT Utrecht, The Netherlands.

    Nadège Charlene Essonghe

    Univ. Lille, Inserm, U1003 – PHYCEL – Physiologie Cellulaire, F-59000 Lille, France; Laboratory of Excellence, Ion Channels Science and Therapeutics, 59655 Villeneuve d’Ascq, France.

    Virginie Poix

    Univ. Lille, CNRS, Inserm, UMR9020-U1277 – CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; Unité tumorigenèse et résistance aux traitements, Institut Pasteur de Lille, F-59000 Lille, France.

    Rebekah Kong

    Univ. Lille, CNRS, Inserm, UMR9020-U1277 – CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; Unité tumorigenèse et résistance aux traitements, Institut Pasteur de Lille, F-59000 Lille, France.

    Patrick Gizzi

    Plateforme de chimie biologique intégrative de Strasbourg, UAR 3286 CNRS – Université de Strasbourg, F-67404 Illkirch, France.

    Claire Bourban

    Plateforme de chimie biologique intégrative de Strasbourg, UAR 3286 CNRS – Université de Strasbourg, F-67404 Illkirch, France.

    Séverine Amand

    Muséum national d’Histoire naturelle, Centre national de la Recherche scientifique, Laboratory Molecules of Communication and Adaptation of Microorganisms (MCAM), UMR 7245 CNRS-MNHN, CP 54, 57 rue Cuvier, 75005 Paris, France.

    Christine Bailly

    Muséum national d’Histoire naturelle, Centre national de la Recherche scientifique, Laboratory Molecules of Communication and Adaptation of Microorganisms (MCAM), UMR 7245 CNRS-MNHN, CP 54, 57 rue Cuvier, 75005 Paris, France.

    Romain Guilbert

    Institut Pasteur de Lille – PLEHTA (Plateforme d’expérimentation et de Haute Technologie Animale), 59019 Lille, France.

    David Hannebique

    Institut Pasteur de Lille – PLEHTA (Plateforme d’expérimentation et de Haute Technologie Animale), 59019 Lille, France.

    Philippe Persoons

    Institut Pasteur de Lille – PLEHTA (Plateforme d’expérimentation et de Haute Technologie Animale), 59019 Lille, France.

    Gwenaëlle Arhant

    Univ. Lille, CNRS, Inserm, UMR9020-U1277 – CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; Unité tumorigenèse et résistance aux traitements, Institut Pasteur de Lille, F-59000 Lille, France.

    Anne Prévotat

    Univ. Lille, Clinique des Maladies Respiratoires, CRCM Hôpital Calmette, CHRU Lille, F-59000 Lille, France.

    Philippe Reix

    CRCM pédiatrique Lyon. Hôpital Femme Mère Enfant. Hospices Civils de Lyon. UMR 5558 (EMET). CNRS, LBBE, Université de Lyon, F-69622 Villeurbanne, France.

    Dominique Hubert

    Pulmonary Department and Adult CF Centre, Cochin Hospital, AP-HP, Paris, France.

    Michèle Gérardin

    CF pediatric centre, Robert Debré hospital, AP-HP, F-75019 Paris, France.

    Mathias Chamaillard

    Univ. Lille, Inserm, U1003 – PHYCEL – Physiologie Cellulaire, F-59000 Lille, France.

    Natalia Prevarskaya

    Univ. Lille, Inserm, U1003 – PHYCEL – Physiologie Cellulaire, F-59000 Lille, France; Laboratory of Excellence, Ion Channels Science and Therapeutics, 59655 Villeneuve d’Ascq, France.

    Sylvie Rebuffat

    Muséum national d’Histoire naturelle, Centre national de la Recherche scientifique, Laboratory Molecules of Communication and Adaptation of Microorganisms (MCAM), UMR 7245 CNRS-MNHN, CP 54, 57 rue Cuvier, 75005 Paris, France.

    George Shapovalov

    Univ. Lille, Inserm, U1003 – PHYCEL – Physiologie Cellulaire, F-59000 Lille, France; Laboratory of Excellence, Ion Channels Science and Therapeutics, 59655 Villeneuve d’Ascq, France.

    Jeffrey Beekman

    Pediatric Respiratory Medicine, Wilhelmina Children’s Hospital, University Medical Center, Utrecht University, 3584 EA Utrecht, The Netherlands; Regenerative Medicine Utrecht, University Medical Center, Utrecht University, 3584 CT Utrecht, The Netherlands; Centre for Living Technologies, University Medical Center, Utrecht University, 3584 CT Utrecht, The Netherlands.

    Fabrice Lejeune

    Univ. Lille, CNRS, Inserm, UMR9020-U1277 – CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; Unité tumorigenèse et résistance aux traitements, Institut Pasteur de Lille, F-59000 Lille, France. Electronic address: fabrice.lejeune@inserm.fr.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement